Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13187472 | 0.83 | CYP1A2 (0.38) | CYP1A2CYP2A6 | |
| SCHEMBL13156327 | 0.76 | BRD4 (0.38) | CYP1A2CYP2A6 | |
| SCHEMBL23487158 | 0.74 | DAO (0.44) | — | |
| SCHEMBL13062636 | 0.73 | MAPT (0.49) | CYP1A2 | |
| SCHEMBL23474198 | 0.71 | LOXL2 (0.50) | CYP1A2CYP2A6 | |
| SCHEMBL7926052 | 0.71 | CYP2A6 (0.43) | CYP1A2CYP2A6 | |
| SCHEMBL29594787 | 0.71 | CYP2A6 (0.43) | CYP1A2CYP2A6 | |
| Hydrochloric Acid SCHEMBL27145114 | 0.70 | LOXL2 (0.49) | CYP1A2CYP2A6 | |
| SCHEMBL18557488 | 0.70 | HRH1 (0.39) | CYP2A6 | |
| SCHEMBL26012345 | 0.69 | ALOX5 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021113686-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2021-06-10 | — | — | WO | disclosed |
| US-20100260715-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100260715-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | CYP1A2 205/4885CYP2A6 283/4885SCN10A 4134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.